Neurocrine Biosciences (NBIX) Change in Receivables: 2010-2021
Historic Change in Receivables for Neurocrine Biosciences (NBIX) over the last 9 years, with Dec 2021 value amounting to $21.7 million.
- Neurocrine Biosciences' Change in Receivables rose 10750.00% to $21.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $28.4 million, marking a year-over-year decrease of 6.89%. This contributed to the annual value of $39.8 million for FY2024, which is 55.43% down from last year.
- Latest data reveals that Neurocrine Biosciences reported Change in Receivables of $21.7 million as of Q4 2021, which was up 309.43% from $5.3 million recorded in Q3 2021.
- Neurocrine Biosciences' Change in Receivables' 5-year high stood at $23.7 million during Q3 2017, with a 5-year trough of -$9.3 million in Q1 2021.
- For the 3-year period, Neurocrine Biosciences' Change in Receivables averaged around $10.7 million, with its median value being $11.0 million (2019).
- Within the past 5 years, the most significant YoY rise in Neurocrine Biosciences' Change in Receivables was 10,750.00% (2021), while the steepest drop was 142.08% (2021).
- Quarterly analysis of 5 years shows Neurocrine Biosciences' Change in Receivables stood at $1.3 million in 2017, then grew by 27.12% to $1.7 million in 2018, then skyrocketed by 579.09% to $11.3 million in 2019, then tumbled by 98.23% to $200,000 in 2020, then surged by 10,750.00% to $21.7 million in 2021.
- Its Change in Receivables stands at $21.7 million for Q4 2021, versus $5.3 million for Q3 2021 and $10.7 million for Q2 2021.